AP2015008742A0 - 5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists - Google Patents

5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Info

Publication number
AP2015008742A0
AP2015008742A0 AP2015008742A AP2015008742A AP2015008742A0 AP 2015008742 A0 AP2015008742 A0 AP 2015008742A0 AP 2015008742 A AP2015008742 A AP 2015008742A AP 2015008742 A AP2015008742 A AP 2015008742A AP 2015008742 A0 AP2015008742 A0 AP 2015008742A0
Authority
AP
ARIPO
Prior art keywords
receptor agonists
carboxamide derivatives
amino quinoline
quinoline
amino
Prior art date
Application number
AP2015008742A
Other languages
English (en)
Inventor
Venkateswarlu Jasti
Anil Karbhari Shinde
Ramakrishna Nirogi
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of AP2015008742A0 publication Critical patent/AP2015008742A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
AP2015008742A 2013-03-20 2013-10-18 5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists AP2015008742A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
IN1199CH2013 IN2013CH01199A (es) 2013-03-20 2013-10-18

Publications (1)

Publication Number Publication Date
AP2015008742A0 true AP2015008742A0 (en) 2015-09-30

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008742A AP2015008742A0 (en) 2013-03-20 2013-10-18 5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Country Status (19)

Country Link
US (1) US9790211B2 (es)
EP (1) EP2976337B1 (es)
JP (1) JP6185650B2 (es)
KR (1) KR101815307B1 (es)
CN (1) CN105164119B (es)
AP (1) AP2015008742A0 (es)
AU (1) AU2013382944B2 (es)
BR (1) BR112015024060A2 (es)
CA (1) CA2907620C (es)
DK (1) DK2976337T3 (es)
EA (1) EA029365B1 (es)
ES (1) ES2674993T3 (es)
HK (1) HK1217483A1 (es)
IN (1) IN2013CH01199A (es)
MX (1) MX364929B (es)
NZ (1) NZ712369A (es)
SG (1) SG11201507763RA (es)
WO (1) WO2014147636A1 (es)
ZA (1) ZA201506804B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975973C (en) * 2015-02-13 2019-07-16 Suven Life Sciences Limited Amide compounds as 5-ht4 receptor agonists
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502273A (ja) * 1992-10-13 1996-03-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5−ht▲下4▼レセプターアンタゴニスト用複素環式エステルまたはアミド
KR950704328A (ko) 1992-11-05 1995-11-17 데이비드 로버츠 5-HT₄ 수용체 길항제로서의 피페리딘 유도체(Piperidine Derivatives as 5-HT₄ Receptor Antagonists)
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
WO2001095902A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab A composition comprising a combination of receptor agonists and antagonists
ES2293262T3 (es) * 2003-06-19 2008-03-16 Janssen Pharmaceutica N.V. 4-(aminometil)-piperidin benzamidas 5ht4-antagonistas.
EP1689742B1 (en) 2003-11-24 2010-03-17 Pfizer, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
DK1701951T3 (da) 2003-12-23 2010-06-07 Serodus As Modulatorer af perifere 5-HT receptorer
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
JP4970290B2 (ja) 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
US7906532B2 (en) 2005-07-22 2011-03-15 Pfizer Inc. Indazole derivatives
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
CA2789663C (en) * 2010-02-12 2018-10-02 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
AU2011216950A1 (en) 2010-02-16 2012-08-23 Pfizer Inc. (R)-4-((4-((4-(tetrahydrofuran-3-yloxy) benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors

Also Published As

Publication number Publication date
KR101815307B1 (ko) 2018-01-04
DK2976337T3 (en) 2018-07-16
JP2016516089A (ja) 2016-06-02
EA201591844A1 (ru) 2016-08-31
EA029365B1 (ru) 2018-03-30
JP6185650B2 (ja) 2017-08-23
CN105164119B (zh) 2017-12-08
CA2907620A1 (en) 2014-09-25
AU2013382944B2 (en) 2016-08-04
NZ712369A (en) 2016-11-25
ES2674993T3 (es) 2018-07-05
EP2976337B1 (en) 2018-05-02
ZA201506804B (en) 2016-07-27
CN105164119A (zh) 2015-12-16
KR20160004274A (ko) 2016-01-12
EP2976337A1 (en) 2016-01-27
US9790211B2 (en) 2017-10-17
AU2013382944A1 (en) 2015-10-08
CA2907620C (en) 2018-03-13
IN2013CH01199A (es) 2015-08-14
HK1217483A1 (zh) 2017-01-13
MX2015012350A (es) 2016-05-09
US20160280694A1 (en) 2016-09-29
WO2014147636A1 (en) 2014-09-25
MX364929B (es) 2019-05-14
SG11201507763RA (en) 2015-10-29
BR112015024060A2 (pt) 2017-07-18
WO2014147636A8 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
HK1215795A1 (zh) 鵝膏毒素衍生物
PT2953944T (pt) Derivados de piridazinona-amidas
HK1217294A1 (zh) '- '- '-氟- '-甲基取代的核苷衍生物
HRP20181141T1 (hr) Derivati purina kao agonisti cb2 receptora
RS56211B1 (sr) Oksohinazolinil-butanamid derivati
IL253848B (en) Amide compounds as 5-hydroxytryptamine 4 receptor agonists
PL3087076T3 (pl) Pochodne imidazopirazynonowe
IL245948B (en) 5–ht4 indazole compounds as receptor agonists
HK1217483A1 (zh) 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物
IL243730A0 (en) Vasopressin-2 receptor agonists
GB201312010D0 (en) Receptor Agonists
HK1220178A1 (zh) 吲跺-甲酰胺衍生物